Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Urogenital Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Colitis 2Carcinoma, Non-Small-Cell Lung 2Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

padeliporfin 5Nivolumab 3vedolizumab 2atezolizumab 2anlotinib 2Therapeutics 2Surveys and Questionnaires 2Riluzole 2Radiotherapy 2LDP-02 2Ipilimumab 2Infliximab 2Immunoglobulin G 2Genetic Testing 2Fecal Microbiota Transplantation 2Disulfides 2Carboplatin 2CT-P13 2tislelizumab 1relatlimab 1prednylidene 1pembrolizumab 1palladium-bacteriopheophorbide 1olaparib 1niraparib 1ixabepilone 1ferumoxtran-10 1enfortumab vedotin 1deltacortene 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Urogenital Neoplasms × vedolizumab × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡